CYP46A1 and Alzheimer disease: The data obtained are of direct clinical relevance as our clinical study of EFV in patients with AD (ClinicalTrials.gov Identifier: NCT03706885) showed the safety of small-dose EFV and CYP46A1 engagement in human brain.